Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aerpio Therapeutics

Request full access

Biotechnology company, develops new small molecules and monoclonal antibodies for the treatment of vascular diseases

Cincinnati, United StatesFounded 2011Biotech & Life Sciences

About Aerpio Therapeutics

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for eye diseases and other vascular-related conditions. The company operates primarily in the healthcare and pharmaceutical markets, targeting conditions such as glaucoma, diabetic nephropathy, and diabetic retinopathy. Aerpio's main clients include healthcare providers, hospitals, and clinics that treat patients with these conditions.

The company’s business model revolves around the research and development (R&D) of novel therapeutics. Aerpio leverages its proprietary technology, particularly the Tie2 pathway, which plays a crucial role in maintaining vascular stability. By activating this pathway, Aerpio aims to develop drugs that can effectively treat diseases caused by vascular dysfunction.

Aerpio's pipeline includes several promising drug candidates. Razuprotafib (AKB-9778) is being tested for its effectiveness in treating open-angle glaucoma and diabetic nephropathy. Another candidate, ARP-1536, is aimed at treating diabetic retinopathy. Additionally, Aerpio is exploring treatments for inflammatory bowel disease (IBD) and certain types of cancer.

The company generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales if the drugs are successfully brought to market. Aerpio also benefits from grants and funding from various health organizations to support its R&D activities.

In summary, Aerpio Pharmaceuticals is a specialized player in the biopharmaceutical sector, focusing on innovative treatments for eye diseases and vascular-related conditions. The company’s revenue model is heavily reliant on strategic partnerships and successful drug development.

Source: Dealroom company data

Aerpio Therapeutics in the Cincinnati ecosystem

Live from Dealroom

The Aerpio Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Venture Investors Health Fund
  • Athenian Venture Partners
  • Kearny Venture Partners
  • Novartis Venture Fund
  • Triathlon Medical Venture Partners

Series B and later1 investor entered at this stage

Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cincinnati HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aerpio Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aerpio Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.